A pediatric case of Miller Fisher syndrome with central involvement. by Ajena, Domenico et al.
LETTER TO THE EDITOR
A pediatric case of Miller Fisher syndrome with central
involvement
D. Ajena • S. Ferrari • S. Romito • F. Zaglia •
P. Biban • G. Squintani
Received: 28 June 2012 / Accepted: 21 September 2012 / Published online: 30 November 2012
 Springer-Verlag Italia 2012
Dear Editor-in-Chief,
Miller Fisher syndrome (MFS) is a rare condition charac-
terized by external ophthalmoplegia, ataxia, and areflexia,
and is considered a clinical variant of Guillain-Barre´ syn-
drome (GBS). Reports on MFS with Bickerstaff brainstem
encephalitis (BBE) overlapping are also reported and a
clear distinction between the two disorders is still debated
[1]. Nevertheless, both clinical pictures are characterized in
up to 90 % of cases by high titre of serum anti GQ1b
antibodies, which have a clear pathogenetic role.
We describe a rare case of pediatric MFS with clinical
central involvement, and a good recovery after the second
cycle of intravenous immunoglobulin (IVIg), suggesting a
therapeutic efficacy of immunomodulatory treatment.
A six-year-old child was referred to our Hospital for acute
onset of diplopia, left palpebral ptosis and sixth left nerve
palsy associated to gait ataxia. The day after, the patient
worsened with drowsiness, ophthalmoplegia, dysphagia and
hypopnea that needed mechanical ventilation. Neurological
evaluation showed generalized hypotonia and weakness with
left predominance, ophthalmoplegia with bilateral ptosis and
severe bilateral facial diplegia. Tendon reflexes were absent,
while no sensory impairment was noted.
Cerebrospinal fluid exam, including protein, cell counts,
microscopic analysis, polymerase chain reaction for neu-
rotrophic viruses, Lyme antibodies and oligoclonal band
research was normal. Blood test analysis was negative for
botulinum toxin, neurotrophic viruses, and antiganglioside
antibody research, with the exception of serum anti-GQ1b
IgG titre obtained using enzyme-linked immunosorbent
assay that was high (1:2,560, normal value \1:640).
Cerebral magnetic resonance imaging (MRI) and elec-
troencephalogram did not show any abnormalities.
Limb neurography was normal except H-reflex recorded
from soleus muscles that was unelicitable; R1 and R2
responses of the blink reflex were absent bilaterally, and
cranial electromyography showed active denervation both
in mouth and eye orbicularis muscles bilaterally. Somato-
sensory evoked potentials (SEP) revealed central impair-
ment (bilateral increased P28 latency: 33.6 ms on the
right and 34.3 ms on the left side, normal value \33.1)
and brainstem auditory evoked potentials (BAEPs)
showed abnormal V/I ratio on the left side (0.39, normal
value [0.5).
A diagnosis of MFS with central involvement was made
and a first cycle of intravenous immunoglobulins (IVIg) at
a standard dose of 0.4 g/kg/die for 5 days was adminis-
trated without clinical improvement. More than 1 month
after the disease onset, estubation was not feasible for the
stable but severe clinical picture, and a second cycle of
IVIg at a standard dose was repeated with significative
clinical benefit: 7 days after, the child was estubated and
discharged from Hospital with mild neurological deficits
(mild bilateral facial, left abducens nerve and mild proxi-
mal limb paresis); serum anti-GQ1b antibody research
became negative.
While MFS is reported in about 5–10 % of GBS forms in
adults, in pediatric population is rare, and clinical reports of
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central-peripheral involvement in children are anecdotal [2].
Recent data suggest that MFS and BBE conditions are not
separate disorders, but rather form a continuous spectrum
called the ‘anti-GQ1b IgG antibody syndrome’ [3] with
variable central and peripheral nervous system involvement.
Nevertheless, pediatric forms are usually mild, with pre-
dominant ocular involvement, even if rarer cases with
transient coma or respiratory failure are described [4].
Our patient demonstrated a predominant brainstem
(cranial nerve) involvement: peripheral nerves conduction
studies were normal except the absence of H-reflex recor-
ded from soleus muscles, whereas cranial motor nerve
conduction studies was severely compromised, showing
bilateral facial muscle denervation. Although the cerebral
MRI did not show any brain damage, the generalized
hypotonia and weakness, the mild drowsiness, the ongoing
hypopnea, associated to SEP and BAEPs abnormalities,
suggested a central involvement probably at the level of
spinocerebellar pathways and brainstem.
Immunological studies with monoclonal anti-GQ1b
antibodies showed a direct pathogenetic role of the anti-
GQ1b in developing MFS symptoms: their binding to
paranodal regions of human ocular motor nerves, muscle
spindles, dorsal root ganglia and deep cerebellar nuclei
may account, respectively, of neuromuscular transmission
impairment and functional block leading to ophthalmo-
plegia, areflexia and peripheral/cerebellar ataxia. The spe-
cific compromission of group Ia muscle spindle afferents,
supported by the evidence of immunolocalization of GQ1b
in human muscle spindles [5], has been proposed as the
responsible mechanism for ataxia and areflexia, and cor-
relates with neurophysiological H-reflex absence (mediated
by group Ia fibers) and normal sensory conduction (that is
carried by group II afferents).
MFS has usually a good prognosis and clinical recovery
is often spontaneous. Randomized controlled trials on
immunomodulatory treatment in MFS and BEE, are still
lacking and a large retrospective study found that, even if
immunosuppressive treatment may hasten the amelioration
of ophthalmoplegia and ataxia, neither IVIg nor plasma-
pheresis influence the patients’ outcomes, because of the
disease natural recovery [6]. Nevertheless, few compro-
mised clinical pictures requiring intubation and mechanical
ventilation may need a therapeutic intervention and the
remarkable clinical improvement in our patient after the
second IVIg cycle suggests the effectiveness of immuno-
modulatory treatment in severe MFS/BEE.
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